Evidence map›Paper›PMID 34824888›Full record

ArticleAmerican journal of blood research2021

Human leukocyte antigen (HLA) alleles as predictive factors for benefit from lenalidomide in acute myeloid leukemia (AML).

Sachin Punatar, Anant Gokarn, Lingaraj Nayak, Avinash Bonda, Sumeet Mirgh, Akanksha Chichra, Meenakshi Singh, Selma D'silva, Navin Khattry

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of blood research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Comparison of Outcomes of Donor Lymphocyte Infusions With or Without Lenalidomide in Patients with Hematological Malignancies Post Allogeneic HSCT.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Sachin PunatarHSCT Unit, Department of Medical Oncology Tata Memorial Centre, HSCT Unit, ACTREC Kharghar, Navi Mumbai 410210, Maharashtra, India.
Anant GokarnHSCT Unit, Department of Medical Oncology Tata Memorial Centre, HSCT Unit, ACTREC Kharghar, Navi Mumbai 410210, Maharashtra, India.
Lingaraj NayakHSCT Unit, Department of Medical Oncology Tata Memorial Centre, HSCT Unit, ACTREC Kharghar, Navi Mumbai 410210, Maharashtra, India.
Avinash BondaHSCT Unit, Department of Medical Oncology Tata Memorial Centre, HSCT Unit, ACTREC Kharghar, Navi Mumbai 410210, Maharashtra, India.
Sumeet MirghHSCT Unit, Department of Medical Oncology Tata Memorial Centre, HSCT Unit, ACTREC Kharghar, Navi Mumbai 410210, Maharashtra, India.
Akanksha ChichraHSCT Unit, Department of Medical Oncology Tata Memorial Centre, HSCT Unit, ACTREC Kharghar, Navi Mumbai 410210, Maharashtra, India.
Meenakshi SinghHomi Bhabha National Institute (HBNI) Anushakti Nagar, Mumbai 410210, India.
Selma D'silvaHomi Bhabha National Institute (HBNI) Anushakti Nagar, Mumbai 410210, India.
Navin KhattryHSCT Unit, Department of Medical Oncology Tata Memorial Centre, HSCT Unit, ACTREC Kharghar, Navi Mumbai 410210, Maharashtra, India.
Homi Bhabha National Institute · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesLenalidomide is an active agent in acute myeloid leukemia (AML); response rates are about 15-30%. There are no well-defined predictive factors for benefit from lenalidomide in AML. One of the mechanisms of lenalidomide is natural killer (NK) cell activation; hence human leukocyte antigen (HLA) class I alleles (serving as killer immunoglobulin-like receptor ligands) could play a predictive role. We here evaluate the same when lenalidomide was used as a bridge to transplant.

methodsConsecutive AML patients started on lenalidomide as bridge to transplant between Aug-2013 to Aug-2018 were included in this single centre retrospective analysis. The starting dose and schedule of lenalidomide were at the discretion of the treating clinician. Lenalidomide was scheduled to be stopped about 2-4 weeks prior to planned transplant admission (or was stopped earlier if there was intolerance). For this study, event was defined as progression/relapse while on lenalidomide or within 4 weeks of stopping the drug. The primary endpoint was event free survival (EFS). Those who underwent transplant without an event were censored on the day of transplant. Toxicities and post-transplant outcomes were secondary endpoints.

resultsTwelve patients (8 males, median age 29 years) were included. At start of lenalidomide, 7 had complete remission (CR)-1 (measurable residual disease or MRD by flow cytometry was positive in 3, negative in 3, and 1 unknown), 4 CR-2 (all MRD negative) and 1 active disease. In the whole cohort, median EFS was not reached with projected 3 year EFS being 80%. There was a significantly reduced risk of event with HLA A*24 (0% vs 75%, P=0.018) or with HLA B*40 (0% vs 60%, P=0.045). Only 1 patient needed discontinuation due to toxicities (cytopenias). Among patients who underwent transplant, grade II-IV acute graft versus host disease (GVHD) was seen in 83%.

conclusionsThis is first study to show that HLA alleles may have a bearing on the effect of lenalidomide in AML and could serve as predictive biomarkers. These findings need to be confirmed in larger prospective studies.

Indexed as

acute myeloid leukemiaHLA allelesLenalidomide

Identifiers

PMID34824888
PMCPMC8610794
OpenAlexW3216165320

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.